Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases 158,000 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner bought 158,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.60 per share, with a total value of $94,800.00. Following the completion of the transaction, the director now directly owns 843,365 shares of the company’s stock, valued at $506,019. This trade represents a 23.05 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Lyell Immunopharma Trading Down 6.5 %

NASDAQ LYEL traded down $0.03 during trading hours on Tuesday, hitting $0.48. 1,199,720 shares of the company’s stock traded hands, compared to its average volume of 1,043,773. The business’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $0.90. The firm has a market capitalization of $142.80 million, a P/E ratio of -0.61 and a beta of -0.41. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds have recently modified their holdings of the company. Centiva Capital LP bought a new position in shares of Lyell Immunopharma in the third quarter worth approximately $31,000. Graham Capital Management L.P. bought a new position in shares of Lyell Immunopharma in the fourth quarter worth approximately $33,000. RPO LLC bought a new position in shares of Lyell Immunopharma in the fourth quarter worth approximately $42,000. Intech Investment Management LLC bought a new position in shares of Lyell Immunopharma in the third quarter worth approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Lyell Immunopharma in the third quarter worth approximately $52,000. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.